2-[4-[5-Methyl-4-[(4-methylphenyl)methyl]-1,2,4-triazol-3-yl]piperidin-1-yl]pyridine | 1338238-33-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[4-[5-Methyl-4-[(4-methylphenyl)methyl]-1,2,4-triazol-3-yl]piperidin-1-yl]pyridine
• CAS: 1338238-33-7
• 化学式: C₂₁H₂₅N₅
• 分子量: 347.463
• InChiKey: KFELQHRSEJMEEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  46.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(吡啶-2-基)哌啶-4-羧酸 在 N-甲基吗啉 、 草酰氯 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 37.5h， 生成 2-[4-[5-Methyl-4-[(4-methylphenyl)methyl]-1,2,4-triazol-3-yl]piperidin-1-yl]pyridine
  参考文献：
  名称：

  Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability

  摘要：

  The V1a receptor has emerged as an attractive target for a range of indications including Raynaud's disease and dysmenorrhoea. As part of an effort to discover a new class of orally active V1a antagonist, we optimised a highly lipophilic, metabolically unstable lead into a range of potent, selective and metabolically stable V1a antagonists. In this communication, we demonstrate the series-dependent effect of limiting the number of rotatable bonds in order to decrease Cytochrome P450-mediated metabolism. This effort culminated in the discovery of PF-184563, a novel, selective V1a antagonist with excellent in vitro and in vivo properties. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.038

文献信息

• Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability
  作者：Patrick S. Johnson、Thomas Ryckmans、Justin Bryans、Dave M. Beal、Kevin N. Dack、Neil Feeder、Anthony Harrison、Mark Lewis、Helen J. Mason、James Mills、Julie Newman、Christelle Pasquinet、Dave J. Rawson、Lee R. Roberts、Rachel Russell、Deborah Spark、Alan Stobie、Toby J. Underwood、Robin Ward、Simon Wheeler

  DOI：10.1016/j.bmcl.2011.08.038

  日期：2011.10

  The V1a receptor has emerged as an attractive target for a range of indications including Raynaud's disease and dysmenorrhoea. As part of an effort to discover a new class of orally active V1a antagonist, we optimised a highly lipophilic, metabolically unstable lead into a range of potent, selective and metabolically stable V1a antagonists. In this communication, we demonstrate the series-dependent effect of limiting the number of rotatable bonds in order to decrease Cytochrome P450-mediated metabolism. This effort culminated in the discovery of PF-184563, a novel, selective V1a antagonist with excellent in vitro and in vivo properties. (C) 2011 Elsevier Ltd. All rights reserved.